1. Home
  2. POET vs RIGL Comparison

POET vs RIGL Comparison

Compare POET & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • POET
  • RIGL
  • Stock Information
  • Founded
  • POET 1972
  • RIGL 1996
  • Country
  • POET Canada
  • RIGL United States
  • Employees
  • POET N/A
  • RIGL N/A
  • Industry
  • POET Semiconductors
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • POET Technology
  • RIGL Health Care
  • Exchange
  • POET Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • POET 278.3M
  • RIGL 247.1M
  • IPO Year
  • POET N/A
  • RIGL 2000
  • Fundamental
  • Price
  • POET $4.01
  • RIGL $26.04
  • Analyst Decision
  • POET Strong Buy
  • RIGL Buy
  • Analyst Count
  • POET 2
  • RIGL 5
  • Target Price
  • POET $5.75
  • RIGL $31.30
  • AVG Volume (30 Days)
  • POET 1.1M
  • RIGL 296.9K
  • Earning Date
  • POET 11-14-2024
  • RIGL 11-07-2024
  • Dividend Yield
  • POET N/A
  • RIGL N/A
  • EPS Growth
  • POET N/A
  • RIGL N/A
  • EPS
  • POET N/A
  • RIGL 0.22
  • Revenue
  • POET $119,946.00
  • RIGL $157,374,000.00
  • Revenue This Year
  • POET N/A
  • RIGL $38.26
  • Revenue Next Year
  • POET $3,437.12
  • RIGL $24.21
  • P/E Ratio
  • POET N/A
  • RIGL $117.60
  • Revenue Growth
  • POET N/A
  • RIGL 21.65
  • 52 Week Low
  • POET $0.72
  • RIGL $7.48
  • 52 Week High
  • POET $5.60
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • POET 53.45
  • RIGL 70.96
  • Support Level
  • POET $3.53
  • RIGL $22.33
  • Resistance Level
  • POET $4.18
  • RIGL $29.16
  • Average True Range (ATR)
  • POET 0.28
  • RIGL 2.34
  • MACD
  • POET 0.02
  • RIGL 0.37
  • Stochastic Oscillator
  • POET 60.76
  • RIGL 76.24

About POET POET Technologies Inc.

POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The group's operations are located in Allentown, PA, Shenzhen, China, and Singapore.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: